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Abstract
Background: Mesothelin is an attractive target for cancer immunotherapy due to its restricted
expression in normal tissues and high level expression in several tumor types including ovarian and
pancreatic adenocarcinomas. Three mesothelin transcript variants have been reported, but their
relative expression in normal tissues and tumors has been poorly characterized. The goal of the
present study was to clarify which mesothelin transcript variants are commonly expressed in
human tumors.
Methods: Human genomic and EST nucleotide sequences in the public databases were used to
evaluate sequences reported for the three mesothelin transcript variants in silico. Subsequently,
RNA samples from normal ovary, ovarian and pancreatic carcinoma cell lines, and primary ovarian
tumors were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and
nucleotide sequencing to directly identify expressed transcripts.
Results: In silico comparisons of genomic DNA sequences with available EST sequences supported
expression of mesothelin transcript variants 1 and 3, but there were no sequence matches for
transcript variant 2. Newly-derived nucleotide sequences of RT-PCR products from tissues and cell
lines corresponded to mesothelin transcript variant 1. Mesothelin transcript variant 2 was not
detected. Transcript variant 3 was observed as a small percentage of total mesothelin amplification
products from all studied cell lines and tissues. Fractionation of nuclear and cytoplasmic RNA
indicated that variant 3 was present primarily in the nuclear fraction. Thus, mesothelin transcript
variant 3 may represent incompletely processed hnRNA.
Conclusion: Mesothelin transcript variant 1 represents the predominant mature mRNA species
expressed by both normal and tumor cells. This conclusion should be important for future
development of cancer immunotherapies, diagnostic tests, and gene microarray studies targeting
mesothelin.
Background
Mesothelin is a glycosylphosphatidylinositol (GPI)-
anchored cell-surface glycoprotein expressed at low levels
by a restricted set of normal adult tissues but aberrantly
expressed by ~70% of human ovarian epithelial tumors
including up to 100% of serous papillary ovarian cancers,
as well as by significant proportions of pancreatic adeno-
carcinomas, endometrioid uterine adenocarcinomas,
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mesotheliomas, and squamous cell carcinomas of the
esophagus, lung and cervix [1-7]. Full length mesothelin
(~69 kD) can be proteolytically cleaved to release a ~33
kD soluble protein corresponding to megakaryocyte
potentiating factor (MPF) [8,9]. The biologic functions of
mesothelin and MPF remain speculative. Mutant mice
with targeted mesothelin gene inactivation are normal,
exhibiting no apparent anatomic, hematologic or repro-
ductive abnormalities [10]. Analysis of the mesothelin
protein sequence yields no strong homologies to known
protein functional domains, beyond a C-terminal GPI-
anchor motif. Mesothelin has been very recently reported
to bind to CA125/MUC16 also commonly expressed on
the surface of ovarian tumor cells [11], suggesting that
mesothelin might play a role in heterotypic cell adhesion
and metastatic spread of ovarian cancer, but data to sup-
port this idea are lacking for most human tumors.
Despite limited understanding of mesothelin's biological
function, its restricted expression by normal tissues com-
bined with frequent abundant expression by tumors has
suggested several applications in clinical oncology. Circu-
lating mesothelin/MPF may have diagnostic potential in
mesothelin-positive malignancies [12], and tumor cell-
associated mesothelin is being used as a target in ongoing
clinical trials of passive immunotherapy using immuno-
toxins [13,14]. Mesothelin may also be a viable antigen
for tumor vaccine therapies (unpublished data presented
by E. Jaffee, 10th Annual SPORE Investigators Workshop,
July 15, 2002). Further, mesothelin appears to be an
important target in the evolving arena of cancer genetic
profiling for several major tumor types [4,5,15-17].
Rational design and development of these potential clini-
cal applications would be facilitated by a clear under-
standing of mesothelin gene and protein expression by
both normal cells and tumors.
To date, three variants of human mesothelin transcripts
have been reported: variant 1 (GenBank accession
NM_005823) encoding MPF [8,9]; variant 2
(NM_013404) encoding mesothelin [18]; and variant 3
(AF180951), a partial alternatively spliced cDNA with a
disrupted GPI-anchor motif [19]. Of note, each transcript
variant has regions of unique oligonucleotide sequences
that could result in differential results in genetic-based
expression studies and further encode proteins with
unique peptides. It is of particular relevance for the
present study that all three mesothelin transcript variants
have been reported to be expressed by human cancer cells.
Nevertheless, there is a remarkable lack of studies directly
investigating relative expression levels of mesothelin tran-
script variants in normal and malignant tissues, even
though multiple gene expression studies of tumor expres-
sion profiles conducted to date have included putative
mesothelin-specific cDNA or oligonucleotide probes
[4,5,15-17]. The present study provides evidence for
expression of human mesothelin transcript variants 1 and
3, but not variant 2, in a variety of human tissues and cell
lines. Moreover, variant 1 appears to be the predominant
mature mesothelin transcript in all studied specimens,
including ovarian and pancreatic adenocarcinomas.
Methods
Cell lines
The human ovarian (SKOV-3, Caov-4, OVCAR-3), pancre-
atic (PANC-1, AsPC-1) and cervical (HeLa) tumor cell
lines were obtained from the American Type Culture Col-
lection (Rockville, MD). UCI 101 human ovarian adeno-
carcinoma cell line was kindly provided by Dr. David T.
Curiel (Gene Therapy Center, University of Alabama at
Birmingham). SKOV-3 cells were grown in McCoy's 5A
medium with 2 mM L-glutamine and 10% FBS. Caov-4,
PANC-1 and HeLa were grown in DMEM with 4.5 g/L glu-
cose, 2 mM L-glutamine and 10% FBS. OVCAR-3 were
grown in RPMI-1640 medium with 2 mM L-glutamine,
1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM
HEPES, 1 mM sodium pyruvate, 0.01 mg/ml bovine insu-
lin and 20% FBS. AsPC-1 and UCI 101 were grown in
RPMI-1640 medium with 2 mM L-glutamine, 1.5 g/L
sodium bicarbonate, 10 mM HEPES, 1 mM sodium pyru-
vate and 10% FBS. Certified FBS was from HyClone
(Logan, UT), insulin was from Sigma (St. Louis, MO), and
all other cell culture media components were from Medi-
atech (Herndon, VA).
Tumor specimens
Ovarian surgical specimens were obtained after informed
consent under protocols approved by the Institutional
Review Board for Human Experimentation of the Univer-
sity of Alabama at Birmingham. Normal ovary was col-
lected at the time of hysterectomy and bilateral salpingo-
oophorectomy. All tissues were collected under sterile
conditions and immediately frozen at -70°C. The 7 ovar-
ian tumor samples used in the present study included 6
designated as endometroid/papillary serous and 1 as pap-
illary serous.
RNA isolation
Total RNA was isolated from frozen tissues and cultured
cell lines by RNA STAT-60 reagent (TEL-Test, Friends-
wood, TX) according to the manufacturer's protocol. Con-
taminating DNA was removed with RQ RNase-free DNase
I (Promega, Madison, WI) and RNA concentration meas-
ured spectrophotometrically (GeneQuant II RNA/DNA
Calculator, Pharmacia Biotech Ltd., Cambridge, United
Kingdom). RNA integrity and quality was analyzed by
electrophoresis on a 1.2% denaturing agarose gel. For
some experiments, nuclear and cytoplasmic RNA were
isolated separately. Briefly, cultured cells were suspended
in TKM buffer (10 mM Tris-HCl pH 7.4, 1 mM KCl, 1 mMBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/19
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MgCl2). After 5 min on ice, 10% Triton-X 100 was added
and the suspension mixed gently. Nuclear and cytoplas-
mic fractions were separated by centrifugation. The
nuclear pellet was lysed by suspension in RNA STAT-60
and processed as above. Cytoplasmic RNA was isolated
from the supernatant fraction by phenol/chloroform
extraction and ethanol precipitation.
Oligonucleotides and RT-PCR
RT-PCR was performed using the Gene Amp PCR kit
(Roche Molecular Systems, Branchburg, NJ) as described
in the manufacturer's protocol, using 1 µg of total RNA as
template with random hexamers for RT priming. Negative
controls without the addition of RT enzyme were per-
formed for each RNA samples. For PCR, oligonucleotide
primers were added at a concentration of 0.3 µM each and
amplification carried out for 35 cycles with an annealing
temperature of 65°C. Negative controls without template
were performed for each PCR amplification. RT-PCR
products were analyzed by electrophoresis on a 1.5%
NuSieve GTG (Cambrex Bio Science Rockland, Rockland,
ME) plus 1% agarose gel, and products visualized by
ethidium bromide staining. PCR primers (Table 1) were
synthesized by Invitrogen Life Technologies (Carlsbad,
CA).
DNA sequencing
Amplified PCR products were either directly sequenced or
first cloned into the pCR4-TOPO vector (Invitrogen) and
subjected to automated dideoxy nucleotide sequencing in
the UAB Center for AIDS Research Sequencing Core Facil-
ity, using fluoresence-based cycle sequencing and the ABI
BigDye Terminator V 3.1 Cycle Sequencing kit with the
ABI Prism 3100 Genetic Analyzer (Applied Biosystems,
Foster City, California, USA). T3 and T7 primers were used
for sequencing genes cloned into pCR4-TOPO: 5'-
ATTAACCCTCACTAAAGGGA-3' and 5'-TAATACGACT-
CACTATAGGG-3'. Sequence data were analyzed by BLAST
nucleotide-nucleotide search (National Center Biotech-
nology Information, http://www.ncbi.nlm.nih.gov/)
against non-redundant and expressed sequence tag (EST)
databases.
Results
In silico analysis of mesothelin transcripts
The NCBI database contains three reported transcripts for
mesothelin/MPF: variant 1 (GenBank accession
NM_005823) encoding MPF/mesothelin [8,9], variant 2
(NM_013404) encoding mesothelin [18], and variant 3
(AF180951) partial cDNA encoding mesothelin with an
alternatively spliced C-terminus [19] (Figure 1). Tran-
script variant 1 was originally reported as MPF derived
from a human pancreatic tumor cell line; the published
sequence is 2085 bp with an opening reading frame of
1869 bp [8,9]. Transcript variant 2 was isolated from a
HeLa cDNA library [18], and the reported sequence is
2107 bp long with an open reading frame of 1887 bp. The
sequences of mesothelin variants 1 and 2 are 98% identi-
cal at the nucleotide level and 95% identical at the amino
acid level. Differences include several amino acid varia-
tions near the N-terminus (amino acids 4–56) and a small
insert in variant 2 compared to variant 1 after amino acid
410 of MPF (NP_005814). Full-length mesothelin/MPF
protein is predicted to be encoded by 17 exons, occupying
approximately 8 kb of human chromosome 16p13.3.
In silico comparison of the reported mesothelin transcripts
with genomic sequences (contig clone NT_037887.3 and
genomic clone AL031258) suggests that the basis for dif-
ferences in the reported transcript 1 and 2 N-terminal
region may have resulted from sequencing errors. Specifi-
cally, differences between amino acids 4–56 are most
readily explained by incorrect sequences generated in GC
rich areas (Figure 2A). The available genomic sequence
matches variant 1, suggesting this variant is correct. Con-
sistent with this, 25 of 25 EST sequences obtained by
BLAST search matched variant 1 in this region, whereas no
EST sequences were found to be identical to variant 2 in
this region.
Table 1: RT-PCR primer pairs used for mesothelin transcript amplification
amplification target sequence, 5' – 3' location expected product size
full length
(tr1 & 2)
ACCCACGGTGCCTCCCTCCC
TCAGGCCAGGGTGGAGGCTAG
exon 1
exon 17
1906 bp (tr1)
1924 bp (tr 2)
24 bp insert
region (tr1 & 2)
CTACCTCTTCCTCAAGATGAG
GTGTCTAGGGTGTCTTTGTCT
exon 12
exon 13
177 bp (tr1)
201 bp (tr2)
82 bp insert
region (tr1 & 3)
ATGAAGCTGCGGACGGATGCG
TGAGAACAGGTCCAGGTCCTA
exon 15
exon 17
262 bp (tr 1)
344 bp (tr 3)
tr3-specific ACCCACGGTGCCTCCCTCCC
ACCTCCACGCCCCCAGCTCTG
exon 1
intron 16
1873 bpBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/19
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Amino acid sequences of mesothelin transcript variants 1, 2 and 3 Figure 1
Amino acid sequences of mesothelin transcript variants 1, 2 and 3. Amino acids in single-letter code are displayed for maximal 
sequence alignment of translated mesothelin variant 1 (tr1, GenBank accession NM_005823), variant 2 (tr2, NM_013404) and 
variant 3 (tr3, AF180951). (.) indicates amino acid identity, and (-) represents gaps for optimal sequence alignment. Note that 
tr3 is a partial cDNA lacking N-terminal sequence.
tr1   MALPTARPLLGSCGTPALGSLLFLLFSLGWVQPSRTLAGETGQEAAPLDGVLANPPNISS   60 
tr2   ...QRLDPCW-...D-RP.............H.A........T.S...G...TT.H....   58 
 
 
tr1   LSPRQLLGFPCAEVSGLSTERVRELAVALAQKNVKLSTEQLRCLAHRLSEPPEDLDALPL  120 
tr2   ............................................................  118 
 
 
tr1   DLLLFLNPDAFSGPQACTRFFSRITKANVDLLPRGAPERQRLLPAALACWGVRGSLLSEA  180 
tr2   ............................................................  178 
 
 
tr1   DVRALGGLACDLPGRFVAESAEVLLPRLVSCPGPLDQDQQEAARAALQGGGPPYGPPSTW  240 
tr2   ............................................................  238 
 
 
tr1   SVSTMDALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPSWRQPERTILRPRFRREVEKT  300 
tr2   ............................................................  298 
tr3                                                           ....    4 
 
tr1   ACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELY  360 
tr2   ............................................................  358 
tr3   ............................................................   64 
 
tr1   PQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQ--------VA  412 
tr2   .........................................D........APRRPLPQ..  418 
tr3   .........................................N........--------..  116 
 
tr1   TLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQ  472 
tr2   ............................................................  478 
tr3   ............................................................  176 
 
tr1   LDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVL  532 
tr2   ............................................................  538 
tr3   ............................................................  236 
 
tr1   PLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQGGIPNGYLVLDLS  592 
tr2   ............................................................  598 
tr3   ............................................................  296 
 
tr1   VQEALSGTPCLLGPGPVLTVLALLLASTLA  622 
tr2   ...T..........................  628 
tr3   ..GGRG.QARAG.RA.G.EVGALSHPSLCRGPLGDALPPRTWTCSHRPGTAPSLHPGLRA 356 
 
 
 
tr3   PLPCWPQPCWGSPPGQEQARVIPVPPQENSRSVNGNMPPADT  398 BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/19
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Human genomic DNA sequence alignment with mesothelin transcript variants Figure 2
Human genomic DNA sequence alignment with mesothelin transcript variants. Selected portions of human genome sequences 
corresponding to the mesothelin gene (AL031258) were aligned with corresponding sequences of reported mesothelin tran-
script variants. (-) represents sequence gaps for optimal alignment. A. The 5'-ends of mesothelin transcript variants 1 and 2 
(tr1, NM_005823; tr2, NM_013404) aligned with the genomic DNA sequence. Lower case letters represent presumed 
untranslated nucleotide sequences. B. Nucleotide sequence at the exon 13 5'-boundary using the same reference database 
sequences as in (A). Lower case letters in the genomic sequence indicate presumed introns for transcript variant 1. Splice 
acceptor sites potentially utilized by transcript variants 1 and 2 are underlined, and the arrowhead indicates a third splice 
acceptor detected by sequence analysis in this study. C. Genomic sequence for the intron 16 region are aligned with sequences 
for transcript variants 1 (tr1, NM_005823) and 3 (tr3, AF180951). Lower case letters represent nucleotides presumed to be 
untranslated for tr1. Expected amino acid sequences are shown above each transcript, highlighting the intron 16 insert and 
reading frame shift predicted for tr3.
C
A
B
genomic  atctctccttgccacaaggctcctcggcggcccctcccacagGTGGCCACCCTG 
tr1                        ------------------------GTGGCCACCCTG 1326 
                           |||||||||||||||||||||||||||||||||||| 
tr2                        GCTCCTCGGCGGCCCCTCCCACAGGTGGCCACCCTG 1348 
 
genomic  ATCGACCGCTTTGTGAAGGGAAGGGGCCAGCTAGACAAAGACACCCTAGACACC  
tr1      ATCGACCGCTTTGTGAAGGGAAGGGGCCAGCTAGACAAAGACACCCTAGACACC 1380 
         |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
tr2      ATCGACCGCTTTGTGAAGGGAAGGGGCCAGCTAGACAAAGACACCCTAGACACC 1402 
 
genomic  CTGACCGCCTTCTACCCTGGGTACCTGTGCTCCCTCAGCCCCGAGGAGCTGAGC  
tr1      CTGACCGCCTTCTACCCTGGGTACCTGTGCTCCCTCAGCCCCGAGGAGCTGAGC 1434 
         |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
tr2      CTGACCGCCTTCTACCCTGGGTACCTGTGCTCCCTCAGCCCCGAGGAGCTGAGC 1456 
 
genomic  TCCGTGCCCCCCAGCAGCATCTG 
tr1      TCCGTGCCCCCCAGCAGCATCTG 1457 
         ||||||||||||||||||||||| 
tr2      TCCGTGCCCCCCAGCAGCATCTG 1479 
genomic     ccctgggatctacacagaccATGGCCTTGCCAACGGCTCGACCCCTGTTGGGGTCCT 
tr1                             ATGGCCTTGCCAACGGCTCGACCCCTGTTGGGGTCCT 121 
                                |||||||||| ||||||||||||||||||||  |||| 
tr2                             ATGGCCTTGC-AACGGCTCGACCCCTGTTGG--TCCT 122 
 
genomic  GTGGGACCCCCGCCCTCGGCAGCCTCCTGTTCCTGCTCTTCAGCCTCGGATGGGTGCAGC 
tr1      GTGGGACCCCCGCCCTCGGCAGCCTCCTGTTCCTGCTCTTCAGCCTCGGATGGGTGCAGC 181 
         |||||  ||  ||||| ||||||||||||||||||||||||||||||||||||||||| | 
tr2      GTGGGGACC—-GCCCT-GGCAGCCTCCTGTTCCTGCTCTTCAGCCTCGGATGGGTGCATC 179 
 
genomic  CCTCGAGGACCCTGGCTGGAGAGACAGGGCAGGAGGCTGCACCCCTGGACGGAGTCCTGG 
tr1      CCTCGAGGACCCTGGCTGGAGAGACAGGGCAGGAGGCTGCACCCCTGGACGGAGTCCTGG 241 
         || ||||||||||||||||||||||||||  |||| |||| |||||||  |||||||||  
tr2      CCGCGAGGACCCTGGCTGGAGAGACAGGGACGGAGTCTGCCCCCCTGGGGGGAGTCCTGA 239 
 
genomic  CCAACCCACCTAACATTTCCAGCCTCTCCCCTCGCCAACTCCTTGGCTTCCCGTGTGCGG 
tr1      CCAACCCACCTAACATTTCCAGCCTCTCCCCTCGCCAACTCCTTGGCTTCCCGTGTGCGG 301 
         | | ||| | |||||||||||||||||||||||||||||||||||||||||||||||||| 
tr2      CAACCCCCCATAACATTTCCAGCCTCTCCCCTCGCCAACTCCTTGGCTTCCCGTGTGCGG 300 
                                                intron 16 
                                                                         
genomic CTGGTCCTAGACCTCAGCATGCAAGgtggcggggcggccaggccagggctgggggcagagctg 
         L  V  L  D  L  S  V  Q  
tr1     CTGGTCCTAGACCTCAGCGTGCAAG-------------------------------------- 1867 
         L  V  L  D  L  S  V  Q  G  G  R  G  G  Q  A  R  A  G  G  R  A  
tr3     CTGGTCCTAGACCTCAGCGTGCAAGGTGGCGGGGCGGCCAGGCCAGGGCTGGGGGCAGAGCTG 934 
 
                        intron 16 
                                                                       
genomic ggggcgtggaggtgggcgctctgagtcacccctctctctgtagAGGCCCTCTCGGGGACGCCC 
                                                   E  A  L  S  G  T  P 
tr1     -------------------------------------------AGGCCCTCTCGGGGACGCCC 1887 
         G  G  V  E  V  G  A  L  S  H  P  S  L  C  R  G  P  L  G  D  A 
tr3     GGGGCGTGGAGGTGGGCGCTCTGAGTCACCCCTCTCTCTGTAGAGGCCCTCTCGGGGACGCCC 997 BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/19
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The other difference between variants 1 and 2 is an eight
amino acid insertion following amino acid 410
(NP_005814). Analysis of the genomic sequence is con-
sistent with the use of an alternative splice acceptor site in
exon 13 (Figure 2B), resulting in an additional 24 bp
insert in variant 2. Based on BLAST searches of expressed
sequences, the 24 bp insert does not appear to be highly
expressed in cancer cells, as only one perfect match was
found in the dbEST database (CB266931); this contrasts
with the adjacent sequence in exon 13 which was identical
to more than 50 ESTs. Thus, analysis of existing sequence
data is consistent with the existence of variant 1, and with
the very rare use of an alternative splice acceptor site in
exon 13 that corresponds to variant 2.
The third reported variant of mesothelin is a partial cDNA
that includes an 82 bp insert near the C-terminus
(AF180951). This sequence, which has not yet been
reported as a full length transcript, is predicted to encode
an alternative C-terminus with a hydrophilic tail that may
produce a secreted form of mesothelin [19]. Genomic
sequence data suggest that this 82 bp insert represents an
unspliced intron 16 (Figure 2C). BLAST search of the
dbEST database with the 82 bp insert sequence indicates
that it is rarely expressed, because no ESTs were found that
were identical to the entire 82 bp sequence.
RT-PCR analysis of mesothelin transcripts
Mesothelin/MPF transcripts expressed in human tissues
and cell lines were analyzed by RT-PCR. Initial studies
used PCR primers corresponding to the 5'-untranslated
region and the 3' stop codon region of both transcript var-
iants 1 and 2 (Table 1, full length), and a single PCR
amplification product was detected in all studied cell lines
and tissue samples (Figure 3). Complete nucleotide
sequences were obtained for amplification products from
the OVCAR-3 cell line, and partial nucleotide sequences
obtained for the 5' regions (≥ 650 nucleotides) of prod-
ucts from HeLa, SKOV-3 and AsPC-1 cells, one normal
ovary and two ovarian tumor samples. These demon-
strated sequence identity to transcript variant 1
(NM_005823), with the exception of a single nucleotide
change (A to G at nucleotide 222, conservative for amino
acid) in HeLa, SKOV-3 and one ovarian tumor sample. In
addition, for HeLa cells and one of the ovarian tumor
samples, nucleotide sequences were also obtained on
amplification products generated using a different set of
mesothelin-specific primers, with identical results. None
of the amplification products corresponded to transcript
2, consistent with the in silico analysis.
To further investigate possible use of the alternative splice
acceptor site in exon 13 of mesothelin, as reported in var-
iant 2, we designed primers in exons 12 and 13 (Table 1,
24 bp insert) and amplified RNA from various cell lines
and tissues. Amplification of a transcript that utilizes the
alternative splice acceptor site (variant 2) should result in
a PCR product of 201 bp. However, only a 177 bp ampli-
fication product consistent with the size expected from
variant 1 was detected (Figure 4B). Nucleotide sequence
analysis of amplification products confirmed use of the
exon 13 splice acceptor site corresponding to transcript
variant 1. We conclude that utilization of the alternative
splice donor site, as reported for variant 2, is rare in both
normal ovary and in pancreatic and ovarian cancer. Inter-
estingly, we also detected a minor amplification product
that was smaller than expected (147 bp, Figure 4B). Clon-
ing and sequence analysis demonstrated that this tran-
script, estimated to comprise less than 5% of the total
mesothelin message, utilized an internal splice acceptor
site in exon 13 (indicated by the arrowhead in Figure 2B),
predicted to encode a protein with an in-frame deletion of
10 amino acids (VATLIDRFVK).
We next investigated expression of mesothelin transcript
variant 3 (AF180951), predicted to encode a form of mes-
othelin with a disrupted GPI-anchor region (exons 16 and
17). PCR primers corresponding to sequences in exons 15
and 17 (Table 1, 82 bp insert) should generate an
amplification product of 262 bp if intron 16 is spliced
from the final transcript, whereas a 344 bp fragment
would be expected if intron 16 is retained (Figure 5A).
Amplification of cDNA from cell lines and tumors dem-
onstrated a predominant product of 262 bp (Figure 5B).
Additional minor products of 344 bp and of a size
RT-PCR analysis of mesothelin transcripts Figure 3
RT-PCR analysis of mesothelin transcripts. Primers designed 
to amplify full length mesothelin from transcript variants 1 
and 2 (Table 1, line 1) were used in RT-PCR analyses of total 
RNA from cell lines and tissues, and analyzed by agarose gel 
electrophoresis. M, molecular size markers; Lane 1, HeLa; 
Lane 2, OVCAR-3; Lane 3, Caov-4; Lane 4, SKOV-3; Lane 5, 
UCI 101; Lane 6, AsPC-1; Lane7, PANC-1; Lanes 8–10, three 
individual normal ovary tissues; Lanes 11–16, six individual 
primary ovarian tumors; Lane 17, no template PCR control.
tumor cell lines
normal
ovary ovarian tumors
M  1   2   3   4   5   6   7   8   9  10  11  12  13  14  15  16 17
1.9 kbBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/19
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between 262 and 344 bp were visualized in all samples.
Sequence analysis demonstrated that the amplified prod-
ucts corresponded to transcript variant 1 (262 bp) and
variant 3 (344 bp), with the middle band representing
heteroduplexes between the two. Relative intensity of the
amplified bands suggested that transcript variant 3 repre-
sents less than 10% of total mesothelin transcripts in the
studied samples.
Because only a partial cDNA sequence for mesothelin var-
iant transcript 3 has been submitted to the public data-
base, RT-PCR analysis was performed using a 3' primer
specific for the 82 bp insert of transcript 3 (intron 16) and
a 5' primer located immediately before the start codon of
transcript 1 (Table 1, tr3-specific). This primer pair should
allow amplification of full length transcripts only from
variant 3. Results using RNA from Caov-4, OVCAR-3,
PANC-1, AsPC-1, HeLa, and 5 ovarian tumor samples
yielded several amplification products including one of
the size expected for full length mesothelin variant 3
(1873 bp, data not shown). Cloning and sequence analy-
sis of individual amplification products demonstrated
that in addition to the predominant product correspond-
ing to variant 3 with an unspliced intron 16, additional
products included unspliced introns 8 and 9, or partial
sequences of other introns. These results raised the
possibility that such transcripts might represent hnRNA
which has not been completely processed.
RT-PCR analysis of potential mesothelin exon 13 splicing dif- ferences between transcript variants 1 and 2 Figure 4
RT-PCR analysis of potential mesothelin exon 13 splicing dif-
ferences between transcript variants 1 and 2. A. Diagram of 
the PCR strategy, showing predicted size of amplified prod-
ucts from transcript variants 1 and 2. PCR primers (Table 1, 
line 2) are indicated by arrows. B. Agarose gel analysis of 
representative RT-PCR results. Lane M, molecular size 
marker; Lane 1, HeLa; Lane 2, OVCAR-3; Lane 3, Caov-4; 
Lane 4, SKOV-3; Lane 5, UCI 101; Lane 6, AsPC-1; Lane7, 
PANC-1; Lanes 8–9, two individual normal human ovaries; 
Lanes 10–14, five individual primary ovarian tumors; Lane 15, 
no template PCR control.
A
M    1   2     3    4    5    6    7    8    9  10  11  12  13  14  15    
tumor cell lines
normal
ovary ovarian tumors
177 bp
147 bp
M    1   2     3    4    5    6    7    8    9  10  11  12  13  14  15    
tumor cell lines
normal
ovary ovarian tumors
177 bp
147 bp
177 bp
147 bp
B
intron 12 exon 12 exon 13 24 bp
↑
↑
transcript 1
transcript 2
177 bp
201 bp
intron 12 exon 12 exon 13 24 bp
↑
↑
intron 12 exon 12 exon 13 24 bp
↑
↑
transcript 1
transcript 2
177 bp
201 bp
transcript 1
transcript 2
177 bp
201 bp
RT-PCR analysis of potential mesothelin exon 16–17 splicing  differences between transcript variants 1 and 3 Figure 5
RT-PCR analysis of potential mesothelin exon 16–17 splicing 
differences between transcript variants 1 and 3. A. Diagram 
of the PCR strategy, showing predicted size of amplified 
products from transcript variants 1 and 3. PCR primers 
(Table 1, line 3) are indicated by arrows. B. Agarose gel anal-
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tion; Lane 4, AsPC-1 nuclear fraction; Lane 5, HeLa cytoplas-
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PCR control.
262 bp
344 bp
tr1
heteroduplex
tr3
M   1     2     3    4     5     6     7    8    9
262 bp
344 bp
tr1
heteroduplex
tr3
M   1     2     3    4     5     6     7    8    9
A
C
2.2 kb
1.8 kb
M     C     N     C     N     C     N     --
OVCAR-3      AsPc-1        HeLa
2.2 kb
1.8 kb
M     C     N     C     N     C     N     --
OVCAR-3      AsPc-1        HeLa
↑
intron 15 exon 15
↑
exon 16 intron 16 exon 17
transcript 1 & 2
transcript 3
262 bp
344 bp
↑
intron 15 exon 15
↑
exon 16 intron 16 exon 17
↑
intron 15 exon 15
↑
intron 15 exon 15
↑
intron 15 exon 15
↑
exon 16 intron 16 exon 17
↑
exon 16 intron 16 exon 17
transcript 1 & 2
transcript 3
262 bp
344 bp
transcript 1 & 2
transcript 3
262 bp
344 bp
BBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/19
Page 8 of 10
(page number not for citation purposes)
To test this possibility, cultured cell lines were fraction-
ated to obtain cytoplasmic RNA (representing fully proc-
essed mature transcripts) and nuclear RNA (which should
include both mature and incompletely processed tran-
scripts). RT-PCR amplification of using the above primers
for mesothelin transcripts containing intron 16 (variant
3) with three cell lines indicated that the intron 16 con-
taining transcripts were primarily amplified from the
nuclear pool of RNA, and only small amounts of product
were recovered from the cytoplasmic RNA (Figure 5C).
Thus, although transcript variant 3 appears to be present
in low levels in both normal and tumor cells, it seems to
be very rare among the cytoplamic fraction of mature,
completely processed RNA.
Discussion
Mesothelin is a promising target for cancer diagnostics
and therapy [12-14,19]. In normal cells, expression is pri-
marily restricted to mesothelial cells in the pleural, peri-
cardial, and peritoneal membranes. Limited mesothelin
immunoreactivity has also been reported in trachea, ton-
sil, fallopian tube and kidney [1]. In contrast, mesothelin
is abundantly expressed in certain tumors, including up to
100% of serous papillary ovarian tumors [5] and up to
100% of pancreatic tumors [4]. Frequent and high level
expression by tumors suggests that mesothelin might play
a role in tumorigenesis. Immunohistochemical studies
demonstrate that mesothelin expression is directly corre-
lated with progressive development of metastatic pancre-
atic cancer [20]. Recent evidence that mesothelin may
promote cell-cell adhesion in ovarian cancer through het-
erotypic binding to CA125/MUC16 further supports a
role in tumor progression [11]. Circulating mesothelin
may serve as a serum marker for early detection and mon-
itoring of mesothelin-positive tumors [12]. However, in
order to fully exploit mesothelin as a target for clinical
applications, it is important to understand mesothelin
expression with regard to the transcript variants that have
been reported to date.
Various investigators have referred to this gene and its
products as mesothelin [18], MPF [8,9], soluble mesothe-
lin [19], mesothelin family members or soluble mesothe-
lin related proteins (SMR) [12]. The in silico and in vitro
studies reported here support mesothelin variant 1 as the
major transcript expressed by both normal and malignant
cells. Mesothelin variant 2 (NM_013404) was not
detected. While it remains possible that nucleotide differ-
ences in variant 2 are the result of allelic variation,
alignment of the transcript variant 2 sequence with avail-
able genomic sequences suggests that the differences in
amino acids 4–56 between variants 1 and 2 may be due to
sequencing errors. Another feature of variant 2, a 24 bp
insertion after base pair 1313 (transcript 2 NM_013404),
appears to arise from use of an alternative splice acceptor
site upstream of the usual splice acceptor site, and was
very rare in our studies. The third reported mesothelin
transcript variant, encoding an alternative C-terminus,
appears to be largely restricted to the nuclear fraction of
RNA and to be infrequent in the cytoplasmic pool of
mature mRNA, suggesting that this variant may represent
incompletely processed hnRNA. Although definitive stud-
ies to detect the soluble isoform of mesothelin protein
predicted to be encoded by variant 3 will be needed to rule
out the possibility of low level expression, data presented
here suggests that variant 1 represents the predominant
form of mesothelin expressed by both normal and tumor
cells.
Despite the presence of a single major transcript for mes-
othelin in the samples evaluated here, immunohisto-
chemical studies of mesothelin protein have reported
distinct expression patterns in tumor samples. In human
pancreatic tumors, some samples exhibited focal staining,
and mesothelin was commonly detected in single tumor
cells surrounded on all sides by stroma; malignant glands
were generally less well stained, but expression was accen-
tuated at luminal borders and luminal contents were fre-
quently positive, suggesting secretion or shedding of
mesothelin from tumor cells [4]. Other analyses of a
variety of tumors, including ovarian cancer, report mes-
othelin staining at the cell membrane, in the cytoplasm,
or both, depending on the sample; staining was some-
times accentuated at apical cell surfaces and in intracyto-
plasmic lumens, with extracellular luminal contents again
noted to be frequently labeled [5,6,19]. Our own immu-
nohistochemical studies of ovarian tumors (unpublished
data) are consistent with the available literature and are
notable in that the pattern of localization of mesothelin is
consistent within a tumor specimen, with some showing
apical localization and apparent secretion of mesothelin,
while cytoplasmic staining is prominent in others.
Given that mesothelin transcript variant 1 is widely and
highly expressed, the basis for differential localization of
mesothelin protein in different tumor samples is most
likely a consequence of post-translational processing.
Mesothelin variant 1 encodes a GPI anchor motif, and
proteins attached to cell plasma membranes by GPI
anchors can be readily released in vivo. A relevant example
is carcinoembryonic antigen (CEA), a tumor-associated
GPI-anchored glycoprotein that is commonly shed by
CEA-positive malignant cells [21]. A furin-like protease
cleavage site within mesothelin that is probably responsi-
ble for the release of the N-terminal MPF portion [9]
could conceivably contribute to mesothelin-immunoreac-
tive extracellular contents observed in tumor tissue
samples and in serum from tumor patients, but evidence
to date suggests that mesothelin-specific antibodies used
for both types of studies react with epitopes in the mem-BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/19
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brane-proximal C-terminal portion of mesothelin. Addi-
tional studies delineating the post-translational
processing and secretion of mesothelin are warranted.
The basis of the reported cross-reactivity of mesothelin
antibodies with other proteins in serum or ascites [19] is
not clear, but is not likely to be due to cross-reactivity with
endogenous homologous proteins. Current databases
contain only one vertebrate gene with significant homol-
ogy to mesothelin, otoancorin (NM_170664), which has
been implicated in autosomal recessive deafness and has
21–22% amino acid identity to mesothelin in the C-ter-
minal region [22]. Interestingly, otoancorin is also located
on human chromosome 16p, but its specific function is
unknown and its expression is apparently limited to the
inner ear.
Conclusions
Mesothelin appears to be predominantly encoded by a
single transcript corresponding the previously reported
mesothelin/MPF variant 1 [8,9]. Although alternative
splicing of the transcript may occur at low levels, the vast
majority of message in primary ovarian tumors, ovarian
and pancreatic tumor cell lines, and normal ovary appears
to be represented by variant 1. Targeting mesothelin tran-
script variant 1 products for future clinical applications is
predicted to be the most valid approach for developing
novel therapies and diagnostic assays for mesothelin-
expressing malignancies.
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